TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01894620

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS real-sham
Description: In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS real-sham
Description: In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS sham-real
Description: In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS sham-real
Description: In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
Study: NCT02877680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T1Doing Well
Description: Strengths-based mobile health (mHealth) app for parents of adolescents with type 1 diabetes, which will prompt parents to recognize and reinforce their adolescents' diabetes-related strength behaviors
Study: NCT02457078

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postnatal Dietary Supplement
Description: Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Supplement
Description: Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
Study: NCT02720783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
Description: Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
Study: NCT01690117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GE-REACH-program
Description: The intervention program Resources to Enhance Alzheimer's Caregivers Health -second step (REACH II) is a multimodal, individualized and structured multi-component intervention program for family caregivers
Study: NCT03103438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089
Study: NCT02720783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus Econazole nitrate 150 mg vaginal pessary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus Benzydamine HCl 6 mg vaginal pessary

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal pessary
Study: NCT01795183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMISULPRIDE
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT02739841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation
Description: 4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physical therapy
Description: The patient will be received vibration and passive of the both upper extremity.
Study: NCT01075321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study: NCT01551121

Intervention type: OTHER
Intervention: It will then allow them to intervene at the right time and the right place
Description: The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.

Intervention type: OTHER
Intervention: It will then allow them to intervene at the right time and the right place
Description: The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
Study: NCT00887471

Intervention type: PROCEDURE
Intervention: PITA or T&A
Description: PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T\&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy

Intervention type: PROCEDURE
Intervention: PITA or T&A
Description: PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T\&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
Study: NCT03660254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tai chi
Description: tai chi exercise intervention，two times a week and each time cost one hour
Study: NCT02475733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime -avibactam
Description: Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
Study: NCT04264416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WB-EMS
Description: 16 weeks of WB-EMS
Study: NCT01075321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03684278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of 5 mg/kg Infliximab
Description: Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of 10 mg/kg Infliximab
Description: Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (Placebo)
Description: 250 ml (500 ml if patient weighs over 100 kg) of 0.9% Sodium Chloride
Study: NCT01075321

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Optional correlative studies
Study: NCT05871489

Intervention type: DRUG
Intervention: Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)
Description: Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed

Intervention type: DRUG
Intervention: Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)
Description: Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed

Intervention type: DRUG
Intervention: Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)
Description: Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed

Intervention type: DRUG
Intervention: Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)
Description: Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed

Intervention type: DRUG
Intervention: Bdq, Lzd, Lfx, Z, Dlm (9-12 months)
Description: Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed
Study: NCT01075321

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Optional correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Optional correlative studies
Study: NCT02030678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan monotherapy (trade name: Aili; batches 180103AG \[40 mg\] and 171231AG \[100 mg\]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
Study: NCT04498884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rinsulin® mix 30/70
Description: one subcutaneous injection at a dose of 0.4 IU/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rinsulin® mix 30/70
Description: one subcutaneous injection at a dose of 0.4 IU/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin® M3
Description: one subcutaneous injection at a dose of 0.4 IU/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin® M3
Description: one subcutaneous injection at a dose of 0.4 IU/kg
Study: NCT02305797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release lorazepam
Description: Extended-release lorazepam capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT03562702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard IV Rehydration Therapy
Description: IV rehydration group receiving a Normal Saline bolus of IVF (usually 20 ml/kg)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV Rehydration Therapy
Description: IV rehydration group receiving a Normal Saline bolus of IVF (usually 20 ml/kg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Therapy (ORT)
Description: Speedlyte oral solution as rehydration therapy based on participant's weight (10 m/l kg over one hour). Total of 150 ml/kg over 24 hours prior to discharge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Rehydration Therapy (ORT)
Description: Speedlyte oral solution as rehydration therapy based on participant's weight (10 m/l kg over one hour). Total of 150 ml/kg over 24 hours prior to discharge
Study: NCT03508830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: 5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
Study: NCT03547648

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peak airway pressure
Description: Patients' peak airway pressures will be raised to observe intraoperative bleeding in thyroidectomy surgery. Aim is to prevent postoperative bleeding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peak airway pressure
Description: Patients' peak airway pressures will be raised to observe intraoperative bleeding in thyroidectomy surgery. Aim is to prevent postoperative bleeding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peak airway pressure
Description: Patients' peak airway pressures will be raised to observe intraoperative bleeding in thyroidectomy surgery. Aim is to prevent postoperative bleeding.
Study: NCT06645990

Intervention type: DEVICE
Intervention: Impella
Description: LV unloading with Impella (ECMELLA) before or within 24 h of ECMO initiation

Intervention type: DEVICE
Intervention: IABP
Description: LV unloading with IABP before or within 24 h of ECMO initiation
Study: NCT02475499

Intervention type: DRUG
Intervention: DPP-4 inhibitors
Description: Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

Intervention type: DRUG
Intervention: GLP-1 analogs
Description: Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

Intervention type: DRUG
Intervention: Sulfonylureas
Description: Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

Intervention type: DRUG
Intervention: Biguanides
Description: Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

Intervention type: DRUG
Intervention: Thiazolidinediones
Description: Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

Intervention type: DRUG
Intervention: Alpha-glucosidase inhibitors
Description: Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

Intervention type: DRUG
Intervention: Meglitinides
Description: Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Study: NCT06014788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPWTi
Description: The wound was filled with black foam (Granufoam®, KCI). The instillation was performed via gravity from i.v. bag through a drain put within the foam. Chlorhexidine 0.1% 300 ml in 700 ml saline was used for continuous instillation three times daily (3 L per day) on the background of continuous pressure of 125 mmHg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional NPWT
Description: Conventional NPWT
Study: NCT03252899

Intervention type: OTHER
Intervention: Survey therapists
Description: A survey was conducted among therapists on upper limb treatment after stroke.

Intervention type: OTHER
Intervention: Survey patients
Description: A survey was conducted among stroke survivors on upper limb treatment after stroke.
Study: NCT04494919

Intervention type: DEVICE
Intervention: Ultrafine Endoscope
Description: The reversal of the normal colonoscope (CV-260SL; Olympus, Tokyo, Japan) along the guidewire to replace the UFE (GIF-XP260NS; Olympus, Tokyo, Japan).
Study: NCT04376996

Intervention type: DIAGNOSTIC_TEST
Intervention: NO intervention planned due to the observational study design - only a diagnostic testing
Description: Only a diagnostic tests are planned: SARS-CoV-2 RNA in nasopharyngeal samples and anti-SARS-CoV-2 antibodies in blood
Study: NCT01807130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated HF/EP Referral
Description: Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Registry Arm)
Description: Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
Study: NCT00503841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Assessed at the time of the initial biopsy and at the time of surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: 14 days prior to surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: 14 days after taking study drug erlotinib hydrochloride.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: 14 days after taking study drug erlotinib hydrochloride.
Study: NCT03486041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavior Modification
Description: Behavior therapy approach to BFRBs involving targeted intervention tactics chosen in accordance with the modality of functioning (ex: Sensory, Cognitive.....) seeming to cause the most frequent and problematic urges to engage in the BFRB. Therapist and client work together, using careful assessments including detailed self-monitoring, to determine what behavioral methods will suffice for lasting change.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention
Description: Weekly brief calls from therapist to check on safety and clinical status. No focus on TTM.
Study: NCT04358926

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen therapy
Description: 8 sessions in 4 days of breathing 100% oxygen in 2.2 ATA. Each session is 60 minutes. 1 meter/minute compression/decompression
Study: NCT03454594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser hemotherapy
Description: semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity
Study: NCT03252899

Intervention type: OTHER
Intervention: Survey patients
Description: A survey was conducted among stroke survivors on upper limb treatment after stroke.
Study: NCT04241380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulant Solutions
Description: Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
Study: NCT05027191

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil Gelatinase-Associated Lipocalin (NGAL)
Description: The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil Gelatinase-Associated Lipocalin (NGAL)
Description: The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.

Intervention type: DRUG
Intervention: Desflurane
Description: Desflurane

Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane
Study: NCT04241380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No anticoagulant solutions
Description: They will receive non-coagulant or coagulant treatment according to clinical conditions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant management
Description: Continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) for a few days.~Aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
Study: NCT00685659

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Outpatient Treatment
Description: 9 hours of group counseling per week for 2-3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive telephone-based counseling
Description: In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm is included

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive telephone-based counseling plus incentives
Description: In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm and monetary incentives for participation are included
Study: NCT04422210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.
Study: NCT04025918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vasopressor automated delivery system
Description: Novel closed-loop system incorporating:~1. Continuous non-invasive arterial pressure (CNAP) monitor that measured and recorded hemodynamic data in real time.~2. Controller algorithm loaded onto a laptop computer that monitored the hemodynamic data from CNAP and determined if vasopressors should be administered.~3. Two syringe pumps loaded with phenylephrine and ephedrine that was activated by the controller algorithm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual vasopressor delivery system
Description: Manual dosing system consisting:~1. Non-invasive intermittent blood pressure monitor that measured and recorded blood pressure at 1-minute intervals.~2. Attending anesthesiologist that noted the blood pressure readings and manually administered phenylephrine or ephedrine according to the algorithm.
Study: NCT01694706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: faldaprevir
Description: medium dose of faldaprevir